Assoc. Prof. Sreeraj vasudevan: HOD Clinical Hematology at Amala Institute of Medical Sciences, India
Dr. Sreeraj V is a highly skilled Clinical Hematologist and Assistant Professor with extensive experience in both the clinical and academic spheres. Over the course of his career, Dr. Sreeraj has developed a deep expertise in managing hematological malignancies, including acute myeloid leukemia (AML), lymphoma, multiple myeloma, and myeloproliferative neoplasms. He is particularly recognized for his work in stem cell transplantation and advanced hematology therapies. Currently, Dr. Sreeraj serves as an Assistant Professor in the Department of Medical Oncology and Hematology at Amala Institute of Medical Sciences, Thrissur, Kerala. He has played a pivotal role in establishing the Hematology and Bone Marrow Transplantation Unit at Amala, where he oversees the management of complex hematological cases. His clinical and research focus is centered on improving patient outcomes through innovative treatments and cutting-edge therapies, including CAR-T cell therapy and bispecific antibody therapies for hematologic malignancies. Alongside his clinical work, he is passionate about medical education, mentoring students, and contributing to the development of hematology professionals across the country.
Online Profiles
Dr. Sreeraj Vasudevan is an Associate Professor at Amala Institute of Medical Sciences, Thrissur, India. He has an active Scopus ID (59197095400) and an ORCID profile for research visibility. His work has garnered 3 citations across 4 documents.
Education
Dr. Sreeraj’s academic journey began with his MBBS from Government Medical College, Thrissur, Kerala, followed by an MD in Medicine from Madurai Medical College, Tamil Nadu, one of the leading institutions in India. His passion for hematology led him to pursue a DM (Doctorate of Medicine) in Hematology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi. Throughout his education, he consistently demonstrated an aptitude for clinical excellence and a strong interest in research, particularly in the field of hematological disorders. The culmination of his education prepared him to lead cutting-edge research and clinical teams in both academic and healthcare settings.
Research Focus
Dr. Sreeraj’s research interests are focused on advancing the diagnosis and treatment of hematological diseases. His primary areas of research include the biology and management of lymphoma, acute myeloid leukemia (AML), and multiple myeloma. He is particularly interested in stem cell transplantation, including both autologous and allogeneic transplants, and has contributed to the development of new therapeutic strategies in this area. His research is also directed toward improving the outcomes for patients undergoing CAR-T cell therapy, an area where he has significantly contributed. Additionally, Dr. Sreeraj is engaged in exploring novel treatments for anemia, myelodysplastic syndromes (MDS), and myeloproliferative disorders, all while working on molecular biomarkers for hematological malignancies. His work has led to the publication of several influential papers that have shaped current practices in hematology.
Experience
With over a decade of clinical and academic experience, Dr. Sreeraj has worked across multiple prestigious institutions in India, including AIIMS, CMC Vellore, and Amala Institute of Medical Sciences, Thrissur. His career began with a rotating internship at Government Medical College, Thrissur, and later included a pivotal year as a rural service physician under the National Rural Health Mission (NRHM). Dr. Sreeraj’s clinical expertise expanded as he worked as an Internal Medicine Physician at Almas Hospital in Kerala and as a Non-Academic Resident in Clinical Hematology at CMC Vellore. In 2017, he joined Amala Institute of Medical Sciences, where he has since become a key figure in both patient care and academic training. In his current role as Assistant Professor in the Department of Medical Oncology and Hematology, Dr. Sreeraj supervises both clinical and research operations, with a specific focus on hematological malignancies and stem cell transplantation. He is instrumental in setting up a comprehensive bone marrow transplant unit at Amala, which serves as a vital resource for patients in Kerala.
Research Timeline & Activities
-
2019-Present: As a lead consultant in Hematology, Dr. Sreeraj initiated and developed a comprehensive bone marrow transplantation program at Amala Institute of Medical Sciences, which includes allogeneic transplants (matched-related, unrelated, and haploidentical) and peripheral blood stem cell harvesting.
-
2020-2021: Dr. Sreeraj’s team began a detailed investigation into the role of bispecific antibodies in the treatment of multiple myeloma, leading to collaborative research projects with international researchers.
-
2022-Present: He is now heavily involved in the clinical development and implementation of CAR-T cell therapy at Amala Institute of Medical Sciences, a pioneering program aimed at improving outcomes for patients with refractory hematological cancers.
-
2023: Dr. Sreeraj’s research into molecular biomarkers in lymphoma and AML has gained recognition at national conferences, contributing to the development of personalized treatment approaches.
-
Ongoing: In addition to his clinical responsibilities, Dr. Sreeraj continues to explore the mechanisms of resistance in AML and lymphoma therapies, collaborating with research institutions to further enhance patient care through targeted therapies.
Awards & Honors
-
Best Researcher Award, AIIMS, New Delhi (2016): Recognized for exceptional research in hematology during his time at AIIMS, particularly in the area of stem cell transplantation.
-
Excellence in Teaching Award, Amala Institute of Medical Sciences, Thrissur (2021): Acknowledged for his dedication to medical education and training the next generation of hematologists, oncologists, and medical professionals.
-
Research Excellence Award, Indian Society of Hematology & Blood Transfusion (2023): Honored for contributions to hematology research, particularly in the areas of lymphoma management and stem cell transplantation.
-
Best Clinical Practice Award, Amrita Institute of Medical Sciences (2019): Recognized for improving clinical protocols and outcomes in hematology patient care.
Top Noted Publication
A specific article titled “Investigation of an Outbreak in a Resource-Limited Setting – Burkholderia cepacia Bloodstream Infection in an Oncology Unit,” which is part of a publication or journal “Reviews and Research in Medical Microbiology” from 2025.
-
Vasudevan, S., Gundarlapalli, S., Thalambedu, N., & Mohan, M. (2022). Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. touchREVIEWS in Oncology & Haematology, 18(1), 59-66. https://doi.org/10.17925/OHR.2022.18.1.59
-
Philip, C., Selvarajan, S., Nayak, L., Jain, H., Kulkarni, U., Samuel, P., Agrawal, N., Kayal, S., Mishra, K., Pavitra, D.S., Jayachandran, P.K., Bala, S.C., Raghavan, V., Paul, M., Singh, J., Vasudevan, S., Mujumdar, S., Nayak, A., Prakash, O., Barath, U., Dharmaraj, A., Rajendra, A., Thorat, J., Bagal, B., Abraham, A., Bhurani, D., Ganesan, P., Sengar, M., & Mathews, V. (2024). Impact of the COVID-19 Pandemic on Treatment of Patients with Acute Myeloid Leukaemia in India. British Journal of Haematology, 205(6), 2058-2062. https://doi.org/10.1111/bjh.19750
-
Singh, S., Lionel, S., Vasudevan, S., Jain, H., et al. (2024). Treatment Challenges and Outcomes of Older Patients with Acute Myeloid Leukemia from India. Annals of Hematology, 103, 4079–4088. https://doi.org/10.1007/s00277-024-05873-y
-
Vasudevan, S., Cyriac, S., Puthillathu, U., Moothiringode Chithrabhanu, S., Aggarwal, S., & Thazhath, A. J. (2022). The Clinical Profile of JAK2 Negative, Normal Erythropoietin, Normal Arterial Oxygen Saturation Erythrocytosis in an Indian Tertiary Centre. Blood, 140(Supplement 1), 12268–12269.
-
Vasudevan, S., Lal, B. M., Vojjala, N., & Mohan, M. (2025). Addressing Practical Challenges with Bispecific Antibody Therapy in Multiple Myeloma. Expert Opinion on Biological Therapy, 25(6), 607–613. https://doi.org/10.1080/14712598.2025.2495984
Innovative Researcher Award Nomination for Dr. Sreeraj Vasudevan
1. Advancing Hematology Treatment with Stem Cell Transplantation and CAR-T Cell Therapy
Dr. Vasudevan has made groundbreaking contributions to hematology, particularly in stem cell transplantation and CAR-T cell therapy for hematological cancers. His leadership in developing the Bone Marrow Transplantation Unit at Amala Institute of Medical Sciences has allowed for the integration of state-of-the-art techniques in hematological care, such as haploidentical and peripheral blood stem cell harvesting. His pioneering role in implementing CAR-T cell therapy in India has significantly impacted patient outcomes in refractory hematologic malignancies, particularly lymphoma and leukemia.
Key Innovation:
-
Developed and implemented advanced stem cell transplantation protocols and CAR-T cell therapy.
-
Significantly improved patient survival rates through personalized and targeted treatments.
2. Targeted Therapeutics: Research on Bispecific Antibodies and Novel Therapies
Dr. Vasudevan’s research into bispecific antibodies as a novel therapeutic strategy for multiple myeloma has resulted in new insights that have reshaped treatment approaches. His work has led to international collaborations and advanced clinical trials, which aim to overcome the challenges posed by traditional therapies.
Key Innovation:
-
Focused on enhancing the effectiveness of bispecific antibody therapies to improve treatment for refractory multiple myeloma.
-
Contributed to a deeper understanding of the challenges and opportunities with bispecific antibody therapies in real-world clinical settings.
3. Molecular Biomarkers and Personalized Medicine in Hematology
His pioneering research into molecular biomarkers for hematologic cancers, such as acute myeloid leukemia (AML) and lymphoma, is enabling more accurate diagnosis and personalized treatment strategies. Dr. Vasudevan’s work aims to identify biomarkers that predict patient responses to therapies, allowing for the development of more targeted and individualized treatment plans, ultimately improving patient outcomes.
Key Innovation:
-
Pioneering work on biomarker discovery that facilitates personalized therapies in AML, lymphoma, and other hematological disorders.
-
Spearheaded efforts to understand mechanisms of treatment resistance, thereby contributing to the development of second-line therapies.
4. Leadership in Medical Education and Mentorship
As an Assistant Professor in the Department of Medical Oncology and Hematology, Dr. Vasudevan has fostered the development of future generations of hematologists and oncologists. His innovative teaching methods and commitment to integrating the latest research into academic curricula have ensured that young doctors are well-versed in emerging therapies and clinical practices.
Key Innovation:
-
Integration of cutting-edge research into medical curricula for the next generation of hematologists.
-
Active mentorship and training programs that are molding future leaders in hematology and oncology.
5. Clinical Leadership and Impact During COVID-19
Dr. Vasudevan played a vital role in adapting clinical practices during the COVID-19 pandemic, with particular focus on hematology patients. His research into the impact of COVID-19 on the treatment of acute myeloid leukemia (AML) patients in India, highlighted in journals such as the British Journal of Haematology, has significantly influenced clinical guidelines for treating hematologic cancer patients during global health crises.
Key Innovation:
-
Conducted pivotal research on COVID-19 and hematological malignancies, leading to changes in treatment protocols for AML patients during the pandemic.
-
Helped shape national treatment strategies and ensure continued care for immunocompromised patients in the midst of the crisis.